AEROVATE THERAPEUTICS INC. - COMMON STOCK

Aerovate Therapeutics to Explore Strategic Alternatives

08 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

17 Jun 2024 07:32:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

21 May 2024 15:15:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

13 May 2024 15:30:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

27 Mar 2024 08:20:59 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

25 Mar 2024 15:10:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

06 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

20 Nov 2023 15:45:16 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

14 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

11 Jul 2023 16:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

22 May 2023 12:15:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

15 May 2023 15:05:01 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

29 Mar 2023 15:50:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

02 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

23 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

17 Nov 2022 06:45:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

14 Nov 2022 06:45:00 By Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

18 Oct 2022 07:00:01 By Nasdaq GlobeNewswire